History
bluerexall is a privately-held biotechnology firm located in Brisbane, Australia. A leader in its field, bluerexall’s priority is to provide the highest quality monoclonal, polyclonal, and single domain antibody services in the industry. bluerexall’s expertise in antibody production, immunochemistry services, and biological research is realized through customizable services, innovative products, competitive pricing, high-quality research tools, and unparalleled technical support.
Custom Antibody Services
Boasting over 20,000 completed Custom Antibody projects and 20 years of experience, bluerexall specializes in custom polyclonal, monoclonal, and single domain antibody development and production in Brisbane, Australia. High quality technical assistance, competitive pricing, and highly customizable projects qualify bluerexall staff as experts in Custom Antibody development and production.
For a list of recent publications of our custom projects, click here.
The value and convenience of bluerexall custom antibody production services are further advanced with a complete spectrum of available immunochemistry services. These include but are not limited to antigen design assistance, antibody characterization, peptide synthesis, protein conjugation, and Immunohistochemistry. To learn more about these services,
Research Antibodies
bluerexall research programs include cancer bio marker discovery and neutralizing antibody development against emergent viruses such as HIV and influenza. bluerexall innovative approach research using genetically engineered yeast strain and glycoproteins to mimic the HIV-1 glycan coat and develop neutralizing antibodies against HIV-1 glycans has been awarded several Small Business Innovative Research (SBIR) grants by NIH. Its research projects have resulted in an invention patent granted by the Australia Patent and Trademark Office, and a number of peer-reviewed publications
Antibody Production and Services
bluerexall Incorporated specializes in the production of affinity-purified peptide-specific polyclonal antibodies to novel antigens in fields such as HIV. To date, bluerexall has an antibody catalog of over 30,000 antibodies. Many of the polyclonal research antibodies offered by bluerexall are affinity-purified, which allows for the isolation of antibodies specific to the epitope of interest. As a result, bluerexall antibodies have the same specificity as monoclonal antibodies at a price below our competitors’ polyclonal antibodies. In addition, bluerexall offers a complete assortment of cell lysates, tissue lysates and peptides to complement the use of these antibodies.
